Compare · NIVF vs PGNY
NIVF vs PGNY
Side-by-side comparison of NewGenIvf Group Limited (NIVF) and Progyny Inc. (PGNY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NIVF and PGNY operate in Misc Health and Biotechnology Services (Health Care), so they compete in similar markets.
- PGNY is the larger of the two at $2.50B, about 554.1x NIVF ($4.5M).
- Over the past year, NIVF is down 99.7% and PGNY is up 44.9% - PGNY leads by 144.6 points.
- NIVF has been more active in the news (7 items in the past 4 weeks vs 2 for PGNY).
- PGNY has more recent analyst coverage (25 ratings vs 0 for NIVF).
- Company
- NewGenIvf Group Limited
- Progyny Inc.
- Price
- $1.34-2.55%
- $31.89+0.02%
- Market cap
- $4.5M
- $2.50B
- 1M return
- -36.25%
- +19.94%
- 1Y return
- -99.74%
- +44.87%
- Industry
- Misc Health and Biotechnology Services
- Misc Health and Biotechnology Services
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- News (4w)
- 7
- 2
- Recent ratings
- 0
- 25
Progyny Inc.
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
Latest NIVF
- SEC Form 4 filed by Director Siu Wing Fung Alfred
- SEC Form 4 filed by Director Fong Hei Yue Tina
- SEC Form 6-K filed by NewGenIvf Group Limited
- NewGen’s Advanced Cytometry Platform Poised for Major UAE/GCC Expansion with Big Four Valuation of US$19 Million
- SEC Form 6-K filed by NewGenIvf Group Limited
- SEC Form 6-K filed by NewGenIvf Group Limited
- NewGen Issues 3,666,667 New Shares in Connection with Strategic K25.ai Acquisition, Reaches Milestone of US$7.6 Million Market Capitalization
- SEC Form 6-K filed by NewGenIvf Group Limited
- NewGen Increases K25.ai Ownership to 10% in Closed Pre-A Round at US$100 Million Valuation with Total US$10 Million Invested
- SEC Form 6-K filed by NewGenIvf Group Limited
Latest PGNY
- Chief Operating Officer Cummings Melissa B covered exercise/tax liability with 1,193 shares and sold $70,910 worth of shares (2,244 units at $31.60) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 69,934 units (SEC Form 4) to satisfy withholding obligation
- Chief Product Officer Clapp Geoffrey covered exercise/tax liability with 819 shares, decreasing direct ownership by 1% to 59,828 units (SEC Form 4) to satisfy withholding obligation
- Amendment: SEC Form SCHEDULE 13G/A filed by Progyny Inc.
- CHIEF FINANCIAL OFFICER Livingston Mark S. covered exercise/tax liability with 1,421 shares and sold $64,184 worth of shares (2,517 units at $25.50) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 74,688 units (SEC Form 4) (tax withholding)
- EVP, GC Swartz Allison covered exercise/tax liability with 1,015 shares and sold $45,022 worth of shares (1,798 units at $25.04) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 82,378 units (SEC Form 4) (for withholding tax)
- CHIEF EXECUTIVE OFFICER Anevski Peter covered exercise/tax liability with 5,361 shares, decreasing direct ownership by 0.66% to 811,472 units (SEC Form 4) to satisfy tax liability
- CHIEF FINANCIAL OFFICER Livingston Mark S. covered exercise/tax liability with 158 shares and sold $7,310 worth of shares (279 units at $26.20) as part of a pre-agreed trading plan, decreasing direct ownership by 0.55% to 78,626 units (SEC Form 4) (withholding tax)
- Director Scott Cheryl exercised 14,667 shares at a strike of $13.00, covered exercise/tax liability with 7,228 shares and sold $196,278 worth of shares (7,439 units at $26.39) (SEC Form 4)
- Chief Product Officer Clapp Geoffrey sold $39,137 worth of shares (1,530 units at $25.58), exercised 12,909 shares at a strike of $20.91 and covered exercise/tax liability with 11,379 shares (SEC Form 4) (for tax liability)
- EVP, GC Swartz Allison covered exercise/tax liability with 1,352 shares and sold $61,053 worth of shares (2,398 units at $25.46) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 85,191 units (SEC Form 4) to cover withholding tax